Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration
International Journal of Molecular Sciences · 01.05.2025 · 26 (9) · 4292
DOI: 10.3390/ijms26094292 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.05.2025. Verfasst von Cara Coleman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) continues to present a therapeutic challenge due to the fact that by definition, these cancer cells lack the expression of targetable receptors. Current treatment options include cytotoxic chemotherapy, antibody–drug conjugates (ADC), and the PD-1 checkpoint inhibitor, pembrolizumab. Due to high rates of recurrence, current guidelines for early-stage TNBC recommend either multi-agent chemotherapy or chemo–immunotherapy in all patients other than those with node-negative tumors < 0.5 cm. This approach can lead to significant long-term effects for TNBC survivors, driving a growing interest in de-escalating therapy where appropriate. Tumor infiltrating lymphocytes (TILs) represent a promising prognostic and predictive biomarker for TNBC. These diverse immune cells are present in the tumor microenvironment and within the tumor itself, and multiple retrospective studies have demonstrated that a higher number of TILs in early-stage TNBC portends a favorable prognosis. Research has also explored the potential of TIL scores to predict the response to immunotherapy. However, several barriers to the widespread use of TILs in clinical practice remain, including logistical and technical challenges with the scoring of TILs and lack of prospective trials to validate the trends seen in retrospective studies. This review will present the current understanding of the role of TILs in TNBC and discuss the future directions of TIL research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
- Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
ORCID-Profile: Cara Coleman
Zitieren
APA
Coleman, C., Selvakumar, T., Thurlapati, A., Graf, K., Pavuluri, S., Mehrotra, S., Sahin, O., & Sivapiragasam, A. (2025). Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration. International Journal of Molecular Sciences, 26(9), 4292. https://doi.org/10.3390/ijms26094292
Vancouver
Coleman C, Selvakumar T, Thurlapati A, Graf K, Pavuluri S, Mehrotra S, et al. Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration. International Journal of Molecular Sciences. 2025;26(9):4292. doi:10.3390/ijms26094292
BibTeX
@article{Coleman2025,
author = {Coleman, Cara and Selvakumar, Tharakeswari and Thurlapati, Aswani and Graf, Kevin and Pavuluri, Sushma and Mehrotra, Shikhar and Sahin, Ozgur and Sivapiragasam, Abirami},
title = {Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {9},
pages = {4292},
doi = {10.3390/ijms26094292}
}
EUVIMED